-
1دورية أكاديمية
المؤلفون: Vidal, Joan Crespi, Gulati, Sasha, Salvesen, Øyvind, Bratbak, Daniel Fossum, Dodick, David W, Matharu, Manjit Singh, Tronvik, Erling Andreas
المصدر: 0 ; 5 ; Cephalalgia Reports
الوصف: Background: Cluster headache (CH) is one of the most painful conditions in humans and there is limited epidemiological data on this debilitating condition. Objectives: To describe the epidemiology of CH in Norway Methods: We conducted a nationwide study to investigate the prevalence, incidence, and comorbidity of CH in Norway between January 1 2008 and December 31 2016. Treatment and outcome data from the Norwegian patient registry and the Norwegian prescription database were linked on an individual basis. Results: Among 3,892,260 individuals ≥18 years old of age, we identified a total of 1891 patients with CH. The prevalence of CH was 48.6 per 100,000, and the male-to-female ratio was 1.47. The estimated incidence of CH was 3.0 per 100,000/year. Among patients with CH, increased age and sex adjusted odds ratios ([OR], all with p-values <0.0001, were observed for medication-induced headache (OR 50.7, 95% CI 36.7–69.9), migraine (OR 25.2, 95% CI 22.5–28.3), chronic posttraumatic headache (OR 22.2, 95% CI 12.8–38.45), history of cranial trauma (OR 1.9, 95% CI 1.5–2.4), somatoform disorders (OR 4.2, 95% CI 3.0–5.8), suicide attempt (OR 3.9, 95% CI 2.6–5.8), personality disorder (OR 3.6, 95% CI 2.6–4.9), bipolar disorder (OR 3.6, 95% CI 2.8–4.8), peptic ulcer (OR 2.8, 95% CI 2.3–3.3), depression (OR 2.8, 95% CI 2.4–3.1), substance abuse (OR 2.6, 95% CI 2.0–3.3), and cerebrovascular disease (OR 2.4, 95% CI 1.8–3.1). Use of opioid analgesics during the study period was more common among patients with CH compared to others (81% vs. 22%, sex and age adjusted OR 23.4, 95% CI 20.8–26.2, p < 0.0001). ; publishedVersion
وصف الملف: application/pdf
العلاقة: Norges forskningsråd: 328615; Cephalalgia Reports. 2022, 5 .; urn:issn:2515-8163; https://hdl.handle.net/11250/3048653Test; https://doi.org/10.1177/25158163221075569Test; cristin:2020475
-
2دورية أكاديمية
المؤلفون: Vidal, Joan Crespi, Gulati, Sasha, Salvesen, Øyvind, Bratbak, Daniel Fossum, Dodick, David W, Matharu, Manjit Singh, Tronvik, Erling Andreas
المصدر: 0 ; 5 ; Cephalalgia Reports
الوصف: Background: Cluster headache (CH) is one of the most painful conditions in humans and there is limited epidemiological data on this debilitating condition. Objectives: To describe the epidemiology of CH in Norway Methods: We conducted a nationwide study to investigate the prevalence, incidence, and comorbidity of CH in Norway between January 1 2008 and December 31 2016. Treatment and outcome data from the Norwegian patient registry and the Norwegian prescription database were linked on an individual basis. Results: Among 3,892,260 individuals ≥18 years old of age, we identified a total of 1891 patients with CH. The prevalence of CH was 48.6 per 100,000, and the male-to-female ratio was 1.47. The estimated incidence of CH was 3.0 per 100,000/year. Among patients with CH, increased age and sex adjusted odds ratios ([OR], all with p-values <0.0001, were observed for medication-induced headache (OR 50.7, 95% CI 36.7–69.9), migraine (OR 25.2, 95% CI 22.5–28.3), chronic posttraumatic headache (OR 22.2, 95% CI 12.8–38.45), history of cranial trauma (OR 1.9, 95% CI 1.5–2.4), somatoform disorders (OR 4.2, 95% CI 3.0–5.8), suicide attempt (OR 3.9, 95% CI 2.6–5.8), personality disorder (OR 3.6, 95% CI 2.6–4.9), bipolar disorder (OR 3.6, 95% CI 2.8–4.8), peptic ulcer (OR 2.8, 95% CI 2.3–3.3), depression (OR 2.8, 95% CI 2.4–3.1), substance abuse (OR 2.6, 95% CI 2.0–3.3), and cerebrovascular disease (OR 2.4, 95% CI 1.8–3.1). Use of opioid analgesics during the study period was more common among patients with CH compared to others (81% vs. 22%, sex and age adjusted OR 23.4, 95% CI 20.8–26.2, p < 0.0001). ; publishedVersion
-
3رسالة جامعية
المؤلفون: Vidal, Joan Crespi
المساهمون: Tronvik, Erling, Gulati, Sasha, Matharu, Manjit Singh
مصطلحات موضوعية: VDP::Medical disciplines: 700
الوصف: Headache disorders are amongst the most prevalent causes of disability worldwide. Most of the effort to develop new therapeutics has focused on migraine. Patients suffering from less common headache disorders such as trigeminal neuralgia (TN) or cluster headache (CH) are also in need of new and better treatments. Our group has developed a new navigation based surgical tool that allows accurate targeting of small anatomical structures that might be involved in cranial and facial pain. Two previous pilot trials have used this technique to inject botulinum toxin type A (BTA) towards the sphenopalatine ganglion (SPG) in 10 patients with intractable chronic CH (1) and in 10 patients with intractable chronic migraine (2). In this Thesis, we further explore the possibilities of this new device. Most of the studies targeting the SPG do not localize the ganglion directly and use anatomical landmarks which have not been validated (3). Our group has depicted the SPG in living humans using MRI for the first time (4). Nonetheless, MRI might not always be available or some patients might have medical contraindications to undergo this examination. For this reason, we developed an algorithm to predict the location of the SPG using bony landmarks identified in CT-scans (paper 1). Classical TN is not classified under trigeminal autonomic cephalalgias but recent studies have shown that one third of the patients might present autonomic symptoms and the SPG has been involved in its pathophysiology. In paper 2, we conducted a pilot study with 10 patients with classical TN (ICHD-3 beta criteria). Patients were injected with 25 units (U) BTA towards the ipsilateral SPG. The primary outcome was the occurrence of adverse events (AEs). The main efficacy outcome was the number of TN attacks at weeks 5-8 after injection compared to baseline. CH is the most common trigeminal autonomic cephalalgia and it inflicts great suffering among patients. The SPG has been involved in its pathophysiology but no other cranial autonomic ganglia have been ...
وصف الملف: application/pdf
العلاقة: Doctoral theses at NTNU;2021:98; Paper 1: Crespi, Joan Vidal; Bratbak, Daniel Fossum; Jamtøy, Kent Are; Tronvik, Erling Andreas. Prediction of the sphenopalatine ganglion localization in computerized tomography images. Cephalalgia 2019 https://doi.org/10.1177/2515816318824690Test Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0Test/); Paper 2: Crespi, Joan Vidal; Bratbak, Daniel Fossum; Dodick, David W.; Matharu, Manjit; Jamtøy, Kent Are; Tronvik, Erling Andreas. Pilot study of injection of onabotulinumtoxinA toward the sphenopalatine ganglion for the treatment of classical trigeminal neuralgia. Headache 2019 ;Volum 59.(8) s. 1229-1239 https://doi.org/10.1111/head.13608Test This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0); Paper 3: Crespi, Joan Vidal; Bratbak, Daniel Fossum; Tronvik, Erling Andreas. Anatomical landmarks for localizing the otic ganglion: A possible new treatment target for headache disorders. Cephalalgia 2019 https://doi.org/10.1177/2515816319850761Test Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0Test/); Paper 4: Crespi, Joan Vidal; Bratbak, Daniel Fossum; Dodick, David W.; Matharu, Manjit; Solheim, Ole; Gulati, Sasha; Berntsen, Erik Magnus; Tronvik, Erling Andreas. Open-label, multi-dose, pilot safety study of injection of onabotulinumtoxinA toward the otic ganglion for the treatment of intractable chronic cluster headache. Headache 2020 ;Volum 60.(8) s. 1632-1643 https://doi.org/10.1111/head.13889Test This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0); urn:isbn:978-82-326-6962-2; urn:issn:2703-8084; https://hdl.handle.net/11250/2735588Test
